Soligenix Q3 net loss narrows on lower R&D costs

Overview

• U.S. rare disease drug developer reported no revenue for Q3 2026

• Net loss narrowed year-over-year due to lower R&D expenses and gain on liabilities

Outlook

• Company expects cash to fund operations into Q2 2028

• Company is evaluating partnerships, licensing, M&A, and government funding opportunities

• Company says maintaining Nasdaq listing is a priority for strategic flexibility

Result Drivers

• LOWER R&D SPENDING - Net loss narrowed mainly due to reduced research and development expenses after termination of FLASH2 trial and HyBryte development

• VENDOR LIABILITIES - Gain on extinguishment of vendor liabilities contributed to lower net loss

Company press release:

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Soligenix Inc is $1.38, about 312.5% above its November 5 closing price of $0.33

Reuters Recommended Reads

• Nov 5 - Janux Therapeutics Q3 net loss narrows on lower R&D expenses

• Nov 5 - Disc Medicine's Q3 net loss narrows on lower R&D expenses

• Nov 5 - Entrada Therapeutics Q3 net loss narrows as expenses fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)